CVS Health Corp. (CVS) shares fell 0.5% to $96.74 as of September 6, 2026, a slight decline from the prior close of $97.20. BestStocks flagged the session as a major change for CVS. The move is tied to price move up. Below, we break down what changed for CVS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
CVS fell 0.5% to $96.74
CVS fell 0.5% in its latest session, moving from $97.20 to $96.74.
Material / EarningsSector-Wide MoveLow confidence
Rel. volume
0.6×
Below Avg
Vs peers
Top 1 of 7 peers
Outperforming
Market cap
$123.4B
New York Stock Exchange
Analyst target
$111
+14.5% vs price
Price chart
Aug 6 – Sep 4
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for CVS Health Corp. investors
For CVS Health Corp. investors, the recent signals add up to a bearish shift. On the constructive side: CVS Health Corp. (CVS) moved +0.36% from $95.33 to $95.67 on 2026-08-10; CVS Health Corp. (CVS) moved +5.76% from $93.72 to $99.12 on 2026-08-05. Weighing against that: Material negative event; Negative session, down 0.5%. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in CVS's fundamentals. Wall Street's consensus price target sits at $110.79, implying +14.5% upside from $96.74. BestStocks rates the overall signal quality low (42/100). With earnings roughly 59 days out, the next report is the most likely near-term test of the move.
CVS price reaction
CVS last traded at $96.74, down $0.46 (-0.47%) from the previous close of $97.20. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -1.1% over the same stretch, leaving CVS ahead of the group by 0.7 points. Over the past month the stock has ranged between $92.90 and $97.60, and it currently sits about 82% of the way up that band.
Bullish and bearish analyst opinions on CVS Health Corp. (CVS)
The consensus analyst price target on CVS Health Corp. (CVS) is $110.79, 14.5% above the recent $96.74. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CVS line up.
▲ The bullish case
+Wall Street's consensus price target of $110.79 implies +14.5% upside from $96.74.
+The Street's most bullish target is $123.00 (+27.1%).
+CVS Health Corp. (CVS) moved +0.36% from $95.33 to $95.67 on 2026-08-10.
+Positive price momentum.
▼ The bearish case
−The most bearish analyst target is $92.00 (-4.9%).
−Material negative event.
−Negative session, down 0.5%.
−CVS Health fell 2.17% to $93.59 as investors absorbed disappointing preliminary 2027 profit guidance released last week, alongside ongoing regulatory scrutiny over its vertically integrated business model and persistent pressures in its pharmacy benefit manager segment.
−CVS Health Corp. moved -5.27% intraday from $104.42 to $98.92.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
CVS Health Corp. (CVS) moved −1.29% from $94.11 to $92.90 on 2026-08-25. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move corresponds to a new 30-day low, with volume near its 5-day average.
Material / Earnings2026-08-21-0.7%
CVS Health Corp. (CVS) moved -1.04% from $94.00 to $93.02 on 2026-08-21. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be technical: CVS reached a new 30-day low on below-average volume (0.8x the 5-day average), and sector peers including Eli Lilly (LLY) moved similarly.
Material / Earnings2026-08-14+2.3%
CVS Health Corp. (CVS) moved +2.71% from $94.60 to $97.16 on 2026-08-14. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a broader sector rally: peers MRK and PFE rose +2.20% and +1.82% respectively on the same day, and CVS volume remained near its 5-day average.
CVS Health fell 2.17% to $93.59 as investors absorbed disappointing preliminary 2027 profit guidance released last week, alongside ongoing regulatory scrutiny over its vertically integrated business model and persistent pressures in its pharmacy benefit manager segment. The decline reflects concerns about Caremark membership losses expected in 2027 due to contract rewrites and pricing model shifts, compounded by renewed calls from lawmakers including Senator Elizabeth Warren for potential structural breakup of integrated healthcare giants. Volume stood at 2.68M shares (0.68x average for this time of day), below typical intraday levels.
Activity2026-08-10-0.0%
CVS Health Corp. (CVS) moved +0.36% from $95.33 to $95.67 on 2026-08-10. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move coincided with CVS reaching a new 30-day low on below-average volume (0.6x the 5-day mean).
CVS Health stock fell 2.69% to $96.45 following Q2 2026 earnings released yesterday, during which the company beat profit expectations and raised 2026 guidance but issued early warnings about 2027. According to WSJ and Yahoo Finance, the selloff centered on management's cautious commentary regarding expected declines in Caremark pharmacy-benefit management membership due to new pricing contract models and insurer client pullbacks, alongside regulatory and cost pressures from the 340B drug-discount program. Volume at 2.58M shares (1.41x average at this point in session) is normal for the time of day.
Material / Earnings2026-08-05-5.1%
CVS Health Corp. (CVS) reported Q2 FY2026 EPS of $2.58 vs. consensus estimate of $1.87, beating by 38.0% on 2026-08-05.
Activity2026-08-05-5.1%
CVS Health Corp. (CVS) moved +5.76% from $93.72 to $99.12 on 2026-08-05. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide rally: three healthcare peers (AMGEN +7.64%, Pfizer +3.12%, Eli Lilly +4.33%) moved in the same direction, though CVS outperformed the peer average by 4.0 percentage points. Volume was 2.6x the 5-day average.
Upcoming catalysts & outlook
Next earnings
2026-11-04 (est.)
in 59 days
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events
Frequently asked questions about CVS
Why did CVS Health Corp. (CVS) stock move?
CVS fell 0.5% to $96.74. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.
How much did CVS stock fall?
CVS lost 0.47% ($0.46) versus the prior close of $97.20, last trading at $96.74 on 0.6× average volume.
When is CVS Health Corp.'s next earnings date?
CVS's next earnings report is estimated for 2026-11-04 — about 59 days away.
What is the analyst price target for CVS?
The consensus analyst price target for CVS is $110.79, about 14.5% above the current $96.74. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.
Is the CVS move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median -1.1% against CVS's -0.5%. CVS ranks top 1 of 7 peers.
How BestStocks tracks CVS
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for CVS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
